Supira Medical, a clinical-stage Shifamed portfolio company, announced the successful completion of an oversubscribed Series E financing round, raising $120M to accelerate the company's mission of transforming the percutaneous ventricular assist device market.

The round was led by new investors Novo Holdings and Qatar Investment Authority, along with participation from two undisclosed strategic investors. Existing investors participated as well, including Cormorant Asset Management and The Capital Partnership, 415 Capital, AMED Ventures, PA MedTech VC fund, and Unorthodox Ventures. Funds will be used to expand Supira's clinical programs for both high-risk percutaneous coronary intervention and cardiogenic shock. This clinical expansion includes the SUPPORT II U.S. Pivotal Study for HRPCI, which will be used to seek FDA PMA approval.